| pubmed-article:14644524 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14644524 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:14644524 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:14644524 | lifeskim:mentions | umls-concept:C0205174 | lld:lifeskim |
| pubmed-article:14644524 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:14644524 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:14644524 | lifeskim:mentions | umls-concept:C0205187 | lld:lifeskim |
| pubmed-article:14644524 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:14644524 | pubmed:dateCreated | 2003-12-3 | lld:pubmed |
| pubmed-article:14644524 | pubmed:abstractText | Our objective was to determine the activity in terms of response rate, surgical resectability, and the tolerability of the new three-drug combination gemcitabine-cisplatin-paclitaxel (GCP) in unresectable stage IIIA(N2) and IIIB non-small cell lung cancer (NSCLC). | lld:pubmed |
| pubmed-article:14644524 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14644524 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14644524 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14644524 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14644524 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14644524 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14644524 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14644524 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14644524 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:14644524 | pubmed:issn | 0169-5002 | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:NelliFabrizio... | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:MartelliOlgaO | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:CrinòLucioL | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:CappuzzoFeder... | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:MaestriAntoni... | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:CalandriCesar... | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:CortesiEnrico... | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:BenedettiGiov... | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:MigliorinoMar... | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:BartoliniStef... | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:RastelliFranc... | lld:pubmed |
| pubmed-article:14644524 | pubmed:author | pubmed-author:AndruccettiMi... | lld:pubmed |
| pubmed-article:14644524 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14644524 | pubmed:volume | 42 | lld:pubmed |
| pubmed-article:14644524 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14644524 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14644524 | pubmed:pagination | 355-61 | lld:pubmed |
| pubmed-article:14644524 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:meshHeading | pubmed-meshheading:14644524... | lld:pubmed |
| pubmed-article:14644524 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14644524 | pubmed:articleTitle | Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer. | lld:pubmed |
| pubmed-article:14644524 | pubmed:affiliation | Division of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy. federico.cappuzzo@ausl.bo.it | lld:pubmed |
| pubmed-article:14644524 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14644524 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:14644524 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:14644524 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14644524 | lld:pubmed |
